Steve Ubl, CEO of the Pharmaceutical Research and Manufacturers of America, said he remains "hopeful" the Trump administration will reconsider its proposal to lower drug prices, according to The Hill.
President Donald Trump has made lowering prescription drug costs for Americans one of his top priorities and has released several proposals to accomplish it. In October, the HHS department proposed lowering Medicare drug prices by establishing an international pricing index that would tie the prices Medicare pays to those in other wealthy countries.
The pharmaceutical industry is fighting the international pricing index..
Mr. Ubl told The Hill that he is "heartened" by a "broad coalition of folks that have raised concerns about this model, not only us."
"I remain hopeful that the secretary is open to better alternatives and, again, I think we want to be responsive to their concerns," Mr. Ubl added.
PhRMA has been meeting with the administration and lawmakers to ensure that they are aware of the organization's concerns.